Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody

TRANSPARENCY COMMITTEE OPINION
Opinions on drugs - Posted on Oct 13 2016

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

No clinical benefit demonstrated in first-line of non-squamous locally advanced or metastatic non-small cell lung cancer.

  • AVASTIN has Marketing Authorisation in combination with platinum-based chemotherapy, in first-line treatment of adult patients with advanced and inoperable, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.
  • It is part of the first-line options in treatment of NSCLC.

Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments